glp 1 glucose dependent insulin secretion GLP-1 Beyond Basal Insulin: How Glucagon-Like

Williams, E., Rudowitz, R., & Bell, C

Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, Sinha RR

Long-term maintenance dosing remains stable for many patients once therapeutic goals are achieved, though periodic reassessment ensures continued appropriateness of therapy

In fact, its probably the biggest barrier to increasing use of this medication. For physicians, another large challenge when prescribing GLP-1RA medications includes lack of clinical guidelines for offlabel prescribing